Organon (OGN) Other Non-Current Assets (2020 - 2025)

Organon (OGN) posted quarterly Other Non-Current Assets of $390.0 million for Q4 2025, up 225.0% on a QoQ basis from $120.0 million in Q1 2021.

Organon (OGN) Other Non-Current Assets (2020 - 2025) Analysis & Trends

Organon has reported Other Non-Current Assets for 3 years, with the latest figure at $390.0 million in Q4 2025.

Other Non-Current Assets for Q4 2025 came in at $390.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $390.0 million (changed N/A YoY), and the FY2025 annual result was $390.0 million, changed N/A from the prior year.
Other Non-Current Assets rose to $390.0 million in Q4 2025, from $120.0 million in the prior quarter.
Over five years, Other Non-Current Assets peaked at $390.0 million in Q4 2025 and troughed at $120.0 million in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn	14.27 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn	10.73 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn	19.60 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn	5.93 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn	-
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn	12.98 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn	4.75 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn	9.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn	3.56 Bn
10	Organon	3.61 Bn	2.48 Bn	847.00 Mn	-

Download Data